Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05619042
Other study ID # CCT2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 7, 2022
Est. completion date January 24, 2024

Study information

Verified date March 2024
Source MultiplAI Health Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to determine the diagnostic accuracy of peripheral whole blood transcriptomes analyzed by an artificial intelligence algorithm to detect the presence and extent of coronary calcification in individuals without a history of known cardiovascular disease. The main question it aims to answer is: 1. Will the proposed method predict the presence and extent of coronary artery calcification from the peripheral whole-blood transcriptomes?


Description:

This study will be a prospective observational single-site study. A convenience sample will be carried out to include 800 patients who attend the Clinic, to undergo a cardiac CT without contrast (coronary calcium score), either for a medical indication or volunteers for an assessment of cardiovascular risk. The study will have a baseline stage in which a clinical evaluation will be performed, blood samples will be drawn for transcriptome analysis and laboratory analysis. Then, a DNA sample obtained by swabbing the buccal mucosa will be taken. Subsequently, a non-contrast gated cardiac CT will be performed to assess the presence and extent of coronary calcification and other outcomes of interest. At the end of patient enrollment, biological samples will be sequenced for in silico evaluation of the results. Finally, a 5-year clinical (telephone) follow-up will be carried out to collect data on the incidence of fatal and non-fatal cardiovascular events.


Recruitment information / eligibility

Status Completed
Enrollment 800
Est. completion date January 24, 2024
Est. primary completion date January 24, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria: - Men and women between 30 and 75 years attending the institution for a non-contrast cardiac CT scan (coronary calcium score) either by medical indication or voluntary for cardiovascular risk assessment. - Signature of the informed consent form Exclusion Criteria: - Previously known chronic renal or hepatic insufficiency. - Active chronic lung disease, defined as exacerbated asthma, exacerbated chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis. - Active and/or previous cardiovascular disease, defined as previous acute myocardial infarction, stable or unstable angina, cerebrovascular accident, history of vascular interventions (coronary or another territory), heart failure, severe cardiomyopathies, or valvulopathies. - Uncontrolled hyper or hypothyroidism. - Suprarenal insufficiency. - Previous surgeries in the last 3 months. - Severe trauma in the last 6 months, defined as one that involved bone fractures and/or surgical interventions. - Known active cancer disease or under treatment (acute or preventive), or history of cancer disease without criteria for a cure. - Known autoimmune disease active or in treatment. - Ongoing pregnancy, postpartum period of fewer than 12 months, or breastfeeding. - Other serious illnesses with an estimated life expectancy of fewer than 12 months (according to the investigators). - Temperature greater than 37.5°C recorded by a thermometer or any acute infection caused by viruses or bacteria confirmed by a health professional in the previous 30 days. - Pathologies under immunosuppressive treatment

Study Design


Locations

Country Name City State
Argentina Clinica Sagrada Familia Ciudad Autonoma de Buenos Aires

Sponsors (2)

Lead Sponsor Collaborator
Santiago Gabriel Miriuka Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Coronary artery calcium score Coronary artery calcium (CAC) score (Agatston units) stratified with increasing risk according to the Society of Cardiovascular Computed Tomography Guidelines as CAC=0; CAC 1-99; CAC 100-299; and CAC=300. At baseline (cross-sectional assessment)
Secondary Coronary artery calcium score Percentile Agatston score: according to age and sex with a increasing risk ranging from 1 to 99 th percentile. At baseline (cross-sectional assessment)
Secondary Coronary artery calcium score (number of segments) Number of segments with coronary calcifications ranging from 0 to 17 segments. At baseline (cross-sectional assessment)
Secondary Aortic valve calcium Aortic valve calcification score (Agatston units) as a continuous variable with increasing risk and without preestablished thresholds At baseline (cross-sectional assessment)
Secondary Thoracic aorta calcium Thoracic aorta calcification score (Agatston units) as a continuous variable with increasing risk and without preestablished thresholds At baseline (cross-sectional assessment)
Secondary Epicardial adipose tissue (volume) cm2/m2 At baseline (cross-sectional assessment)
Secondary Epicardial adipose tissue (density) density, Q1-Q4: quartiles percentage At baseline (cross-sectional assessment)
Secondary Fatty liver liver attenuation <48 Hounsfield units At baseline (cross-sectional assessment)
Secondary Neutrophil to lymphocyte ratio hematological parameter for systemic inflammation and stress At baseline (cross-sectional assessment)
Secondary High-sensitive C reactive protein (CRP) mg/dl At baseline (cross-sectional assessment)
Secondary Repolarization abnormalities Number of participants with repolarization abnormalities on a 12-lead ECG, defined as ST segment depression or pathological T wave inversion. At baseline (cross-sectional assessment)
Secondary Left ventricular hypertrophy Number of participants with left ventricular hypertrophy on a 12-lead ECG, defined by positive Sokolow-Lyon or Cornell criteria. At baseline (cross-sectional assessment)
Secondary Intraventricular conduction abnormalities Number of participants with intraventricular conduction abnormalities on a 12-lead ECG, stratified by the presence of left bundle branch
block; right bundle branch block and left posterior fascicular block; right bundle branch block and left anterior fascicular block or right bundle branch block; or left anterior fascicular block.
At baseline (cross-sectional assessment)
Secondary Percent electron density relative to water (%EDW) percent electron density relative to water, available for direct evaluation with dedicated software in all scans acquired using a dual-layer spectral CT scanner). At baseline (cross-sectional assessment)
Secondary Death Number of participants with report of death from any cause year 1 through 5
Secondary Acute ischemic syndrome Number of participants with non fatal diagnosis of acute myocardial infarction or unstable angina year 1 through 5
Secondary Heart failure Number of participants with non fatal new diagnosis of heart failure with preserved or impaired ventricular function year 1 through 5
Secondary Vascular revascularization Number of participants with performance of myocardial revascularization surgery, coronary angioplasty or peripheral vascular angioplasty year 1 through 5
Secondary cerebrovascular event Number of participants with non fatal diagnosis of cerebrovascular accident ("stroke") or transient ischemic attack year 1 through 5
Secondary Cancer Number of participants with new diagnosis of any type of cancer year 1 through 5
See also
  Status Clinical Trial Phase
Recruiting NCT05052918 - The Effect of Exercise and Metformin on Carotid Intima-media Thickness in Patients With Prediabetes N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Completed NCT05906797 - Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Periodontitis. N/A
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Suspended NCT02932176 - Machine Learning for Handheld Vascular Studies
Recruiting NCT05158257 - Clinical Of Plain Balloon Dilatation Combined Stent Versus Endovascular Debulking Combined Drug-coated Balloon to Treat Arteriosclerosis Occlusive Disease of Lower Extremity N/A
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT03697382 - Effect of Daily Steps on Fat Metabolism N/A
Recruiting NCT06230406 - T-Mem GEne in Atherosclerosis
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02894931 - Effects of Dietary Interventions on Serum and Macrophage Atherogenicity N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
Completed NCT02224339 - New Technologies to Determine Carotid Plaque Vulnerability
Completed NCT02268513 - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study
Completed NCT03393377 - Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination N/A
Not yet recruiting NCT01923012 - Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis Phase 2
Completed NCT02116829 - Is There Room for Butter in a Healthy Diet? N/A